Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 29, 2024Diabetes Obesity and MetabolismOpen Access

Fenofibrate and risk of end‐stage renal disease: A nationwide cohort study

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYoung Youl HyunKKKyung‐Soo KimSHSangmo Hong

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hyun et al. (2024) studied this question.

synapsesocial.com/papers/68e5ea28b6db64358757e907https://doi.org/10.1111/dom.15815
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Fenofibrate to prevent amputation and reduce vascular complications in patients with diabetes: FENO-PREVENT2024 · 13 citations
  2. 2Effects of Long-Term Fenofibrate Treatment on Markers of Renal Function in Type 2 Diabetes2009 · 82 citations
  3. 3Fenofibrate’s impact on cardiovascular risk in patients with diabetes: a nationwide propensity-score matched cohort study2024 · 9 citations
  4. 4#1614 Fenofibrates and chronic kidney disease – Is there anything to worry about?2024
  5. 5Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence2026